Skip to main content
. Author manuscript; available in PMC: 2014 Dec 1.
Published in final edited form as: Clin Pharmacol Ther. 2013 Jul 17;94(6):10.1038/clpt.2013.143. doi: 10.1038/clpt.2013.143

Table 1.

Anthropometric, physiologic and clinical characteristics of Caucasian PAH study population.

Number of patients 56
Age (yr) 51 ± 131
Sex M : F (%) 29 : 71
BMI (kg/m2) 30.8 ± 7.6
History of liver disease (%) 8.9
Bosentan exposure (g/m2) 611 ± 677
CYP2C9 inhibitors (%) 5.3
CYP3A4 inhibitors (%) 8.9
MRP2 inhibitors (%) 3.6
BSEP inhibitors (%) 0
OATP1B1 inhibitors (%) 57.1
OATP1B3 inhibitors (%) 0
1

Data is presented as either mean ± S.D. or percent of total group.